AU2019395288B2 - Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds - Google Patents
Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds Download PDFInfo
- Publication number
- AU2019395288B2 AU2019395288B2 AU2019395288A AU2019395288A AU2019395288B2 AU 2019395288 B2 AU2019395288 B2 AU 2019395288B2 AU 2019395288 A AU2019395288 A AU 2019395288A AU 2019395288 A AU2019395288 A AU 2019395288A AU 2019395288 B2 AU2019395288 B2 AU 2019395288B2
- Authority
- AU
- Australia
- Prior art keywords
- perampanel
- group
- pharmaceutical formulation
- hydrate
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779620P | 2018-12-14 | 2018-12-14 | |
| US62/779,620 | 2018-12-14 | ||
| PCT/US2019/066622 WO2020124090A1 (en) | 2018-12-14 | 2019-12-16 | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019395288A1 AU2019395288A1 (en) | 2021-09-23 |
| AU2019395288B2 true AU2019395288B2 (en) | 2025-04-03 |
Family
ID=69174604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019395288A Active AU2019395288B2 (en) | 2018-12-14 | 2019-12-16 | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12303499B2 (https=) |
| EP (1) | EP3893844A1 (https=) |
| JP (1) | JP7177937B2 (https=) |
| KR (1) | KR102912861B1 (https=) |
| CN (1) | CN113226286B (https=) |
| AU (1) | AU2019395288B2 (https=) |
| BR (1) | BR112021010953A2 (https=) |
| CA (1) | CA3122705A1 (https=) |
| MA (1) | MA54460A (https=) |
| MX (1) | MX2021006317A (https=) |
| WO (1) | WO2020124090A1 (https=) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104706604A (zh) * | 2013-12-12 | 2015-06-17 | 北京星昊医药股份有限公司 | 一种吡仑帕奈冻干口崩片及其制备方法 |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356902A (en) | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
| IL109397A0 (en) | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| HU219777B (hu) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
| DK0784054T3 (da) | 1994-09-27 | 2002-03-25 | Yamanouchi Pharma Co Ltd | 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister |
| US5935551A (en) | 1995-11-15 | 1999-08-10 | California Institute Of Technology | Synthesis of zeolites by hydrothermal reaction of zeolite P1 |
| DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
| CN1103772C (zh) | 1996-05-15 | 2003-03-26 | 辉瑞大药厂 | 新的2,3－二取代－4(3h)－喹唑啉酮类化合物 |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| SK113299A3 (en) | 1997-02-28 | 2001-05-10 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
| GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
| WO2000001376A2 (en) | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| DE19835918A1 (de) | 1998-08-07 | 2000-02-10 | Dresden Arzneimittel | Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung |
| ES2320973T3 (es) | 2000-06-12 | 2009-06-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos. |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| US7803818B2 (en) | 2005-12-21 | 2010-09-28 | Eisai R&D Management Co., Ltd. | Amorphous form of 1,2-dihydropyridine compound |
| WO2008111590A2 (en) | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | Ampa and nmda receptor antagonists for neurodegenerative diseases |
| JP2015227288A (ja) * | 2012-08-31 | 2015-12-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | けいれん重積発作の治療用医薬組成物 |
| CN104644592A (zh) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种吡仑帕奈药物组合物及其制备方法 |
| CA2973140C (en) * | 2015-02-06 | 2025-09-16 | Marinus Pharmaceuticals, Inc. | Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders |
| CN106389367B (zh) | 2016-11-16 | 2020-12-18 | 杭州朱养心药业有限公司 | 吡仑帕奈包衣片剂药物组合物 |
-
2019
- 2019-12-16 MA MA054460A patent/MA54460A/fr unknown
- 2019-12-16 KR KR1020217017514A patent/KR102912861B1/ko active Active
- 2019-12-16 CA CA3122705A patent/CA3122705A1/en active Pending
- 2019-12-16 WO PCT/US2019/066622 patent/WO2020124090A1/en not_active Ceased
- 2019-12-16 CN CN201980081856.7A patent/CN113226286B/zh active Active
- 2019-12-16 AU AU2019395288A patent/AU2019395288B2/en active Active
- 2019-12-16 JP JP2021530970A patent/JP7177937B2/ja active Active
- 2019-12-16 EP EP19839214.4A patent/EP3893844A1/en active Pending
- 2019-12-16 US US17/312,077 patent/US12303499B2/en active Active
- 2019-12-16 BR BR112021010953-6A patent/BR112021010953A2/pt unknown
- 2019-12-16 MX MX2021006317A patent/MX2021006317A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104706604A (zh) * | 2013-12-12 | 2015-06-17 | 北京星昊医药股份有限公司 | 一种吡仑帕奈冻干口崩片及其制备方法 |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019395288A1 (en) | 2021-09-23 |
| CN113226286B (zh) | 2024-08-20 |
| WO2020124090A1 (en) | 2020-06-18 |
| US20220023275A1 (en) | 2022-01-27 |
| MA54460A (fr) | 2021-10-20 |
| US12303499B2 (en) | 2025-05-20 |
| KR20210107644A (ko) | 2021-09-01 |
| KR102912861B1 (ko) | 2026-01-15 |
| JP7177937B2 (ja) | 2022-11-24 |
| MX2021006317A (es) | 2021-08-11 |
| EP3893844A1 (en) | 2021-10-20 |
| JP2022510947A (ja) | 2022-01-28 |
| CN113226286A (zh) | 2021-08-06 |
| BR112021010953A2 (pt) | 2021-08-24 |
| CA3122705A1 (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101435296B1 (ko) | 아세나핀을 함유하는 주사가능한 제제 및 그를 사용한 치료 방법 | |
| JP2021073235A (ja) | （Ｓ）−４−（８−アミノ−３−（１−（ブト−２−イノイル）ピロリジン−２−イル）イミダゾ［１，５−ａ］ピラジン−１−イル）−Ｎ−（ピリジン−２−イル）ベンザミドの固体形態及び製剤 | |
| JP6106228B2 (ja) | 過増殖性疾患、自己免疫疾患、および心疾患の治療のための３−キヌクリジノンを含有する水溶液 | |
| CA3128018A1 (en) | Therapeutic compounds and compositions | |
| CN109996787B (zh) | 难溶性复合物或其溶剂合物、药物组合物及其应用 | |
| AU2018303293A1 (en) | Amorphous form of vilanterol trifenatate and processes for the preparation thereof | |
| JP5993933B2 (ja) | 安定性を改善したオタミキサバン製剤 | |
| AU2019395288B2 (en) | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds | |
| WO2017167837A1 (en) | Cyclodextrin-panobinostat adduct | |
| EP1621202B1 (en) | Freeze-dried preparation containing methylcobalamin and process for producing the same | |
| RU2824582C2 (ru) | Водные фармацевтические составы на основе 1,2-дигидропиридиновых соединений | |
| NL8102362A (nl) | Farmaceutische antitumor-preparaat; werkwijze voor de bereiding daarvan. | |
| CN100428937C (zh) | 左西孟旦冷冻干燥组合物 | |
| Baraldi et al. | Cocrystallization of Caffeine with Carboxylic Acids and Flavonoids: In Vitro Study to Control the “Caffeine Crash” | |
| Couto | Association of capsaicin with local anesthetics to increase analgesia | |
| HK1236852B (zh) | 用於治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液 | |
| O'Donnell | Pharmaceutical technologies for improving drug loading in the formulation of solid dispersions | |
| NZ723869B2 (en) | Aripiprazole formulations having increased injection speeds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 14 SEP 2021 |
|
| FGA | Letters patent sealed or granted (standard patent) |